Can Ajovy Cause Upper Respiratory Infection Symptoms?
No, Ajovy (fremanezumab) does not directly cause upper respiratory infection (URI) symptoms, but injection site reactions are the most common side effect reported in clinical trials. 1
Understanding the Side Effect Profile
According to the FDA-approved prescribing information, the most common side effects of Ajovy include injection site reactions 1. The drug label does not list upper respiratory symptoms (such as nasal congestion, rhinorrhea, sore throat, or cough) as recognized adverse effects of fremanezumab.
What the Clinical Trial Data Shows
In pooled analysis of phase 3 trials involving 2,842 patients with episodic and chronic migraine:
- Overall adverse events occurred in 58-65% of patients across both fremanezumab and placebo groups
- Serious adverse events were rare (<1-2%) and occurred at similar rates to placebo
- No specific upper respiratory symptoms were identified as treatment-related adverse events 2
The safety profile remained favorable regardless of cardiovascular risk factors or concurrent medication use 2.
Important Clinical Distinction
If a patient on Ajovy develops URI symptoms, this most likely represents:
Coincidental viral upper respiratory infection - These are extremely common, with approximately 37 million ambulatory care visits annually in the United States for the common cold alone 3
Unrelated to fremanezumab therapy - The temporal association does not establish causation
What to Look For Instead
The FDA label specifically warns about allergic reactions that can occur within hours to 1 month after receiving Ajovy, which may include 1:
- Swelling of face, mouth, tongue, or throat
- Trouble breathing
- Itching, rash, and hives
These hypersensitivity reactions are distinct from typical URI symptoms and require immediate medical attention.
Clinical Pitfall to Avoid
Do not attribute common viral URI symptoms to Ajovy without considering more likely etiologies. The evidence shows fremanezumab has a favorable safety profile with injection site reactions as the primary concern, not respiratory symptoms 2, 4, 5.
If URI symptoms develop, manage according to standard clinical guidelines for viral upper respiratory infections with supportive care 3, while continuing to monitor for the actual known adverse effects of fremanezumab (injection site reactions and potential allergic reactions).